Role of photodynamic therapy in polypoidal choroidal vasculopathy

Indian J Ophthalmol. 2005 Jun;53(2):101-4. doi: 10.4103/0301-4738.16172.

Abstract

Purpose: To evaluate photodynamic Therapy (PDT) with Verteporfin for polypoidal choroidal vasculopathy (PCV) involving the fovea in Indian eyes, through a retrospective interventional case series.

Materials and methods: We retrospectively reviewed the records of 9 patients (9 eyes) diagnosed to have PCV with foveal involvement between September 2001 and October 2002.

Results: Nine eyes underwent PDT for PCV. Follow-up ranged from 12 to 16 months. Initial visual acuity (VA) ranged from 1/60 to 6/12 and final VA varied from 1/60 to 6/9 at the end of follow-up. VA improved in 4/9 eyes (44.4%) by one line and remained unchanged in 5/9 eyes (55.6%), hence it was considered stabilized in all eyes. No adverse effects or events were observed during or after treatment with verteporfin.

Conclusion: PDT may be beneficial for PCV with foveal involvement. Its long-term efficacy requires to be evaluated.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Choroid / blood supply*
  • Choroid Diseases / diagnosis
  • Choroid Diseases / drug therapy*
  • Coloring Agents
  • Female
  • Fluorescein Angiography
  • Fovea Centralis
  • Humans
  • Indocyanine Green
  • Male
  • Middle Aged
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use*
  • Pigment Epithelium of Eye / pathology
  • Porphyrins / therapeutic use*
  • Retrospective Studies
  • Treatment Outcome
  • Verteporfin
  • Visual Acuity

Substances

  • Coloring Agents
  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin
  • Indocyanine Green